HBV vaccine developer Hookipa Pharma granted $5 million milestone payment under agreement with Gilead

By The Science Advisory Board staff writers

January 4, 2023 -- Hookipa Pharma, the developer of a new class of immunotherapies using an arenavirus platform, on Wednesday announced that it has been granted a $5 million milestone payment under a collaboration agreement with Gilead Sciences.

Hookipa said it completed and delivered a regulatory support package for Gilead's Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using the developer's arenaviral platform.

The first participant in the Phase 1 clinical trial is expected to be dosed in 2023.

"Chronic hepatitis B infection remains an area of considerable unmet need, and we look forward to seeing the potential impact of our novel arenaviral platform as a component of care," Joern Aldag, CEO of Hookipa, said in a statement.

Preclinical data on the hepatitis B vaccine as a potential component for a curative regimen were recently presented at the American Association for the Study of Liver Diseases (AASLD).

Gilead is solely responsible for further development and commercialization of the hepatitis B product candidate.

Hookipa noted that it is eligible to receive milestone payments based on the achievement of specified development, regulatory, and commercial milestones up to a total of more than $190 million, and it is also eligible to receive tiered royalties on net sales.

New treatment from Sweden for hepatitis B, D shows promise in mice
Researchers at Karolinska Institutet in Sweden have developed a new type of treatment for chronic hepatitis B virus and hepatitis D virus infections...
Precision BioSciences highlights hepatitis B virus drug research
Precision BioSciences is highlighting new research showing that its gene editing drug candidate targeting the hepatitis B virus (HBV) achieved an 85%...
VBI touts positive hepatitis B vaccine results
VBI Vaccines' prophylactic 3-antigen hepatitis B vaccine candidate offers better protection from the disease than the mono-antigenic vaccine Engerix-B,...
FDA accepts VBI's hepatitis B vaccine BLA
The U.S. Food and Drug Administration (FDA) has accepted the biologics license application (BLA) submitted by VBI Vaccines for its 3-antigen prophylactic...

Copyright © 2023 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter